Loading...
XNAS
VYNE
Market cap6mUSD
Jul 30, Last price  
0.40USD
1D
-72.35%
1Q
-70.29%
IPO
-99.79%
Name

Vyne Therapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
13.24
EPS
—
Div Yield, %
—
Shrs. gr., 5y
146.14%
Rev. gr., 5y
2.49%
Revenues
501k
+18.16%
0674,0004,582,00010,640,000443,00020,993,00014,755,000477,000424,000501,000
Net income
-40m
L+40.00%
-4,608,000-14,068,000-29,076,000-51,445,000-70,464,000-255,568,000-73,329,000-33,945,000-28,452,000-39,834,000
CFO
-34m
L+34.06%
-4,183,000-2,291,000-28,247,000-52,733,000-65,101,000-137,082,000-56,367,000-29,200,000-25,341,000-33,972,000
Earnings
Aug 12, 2025

Profile

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
URL
https://vynetherapeutics.com/
IPO date
Jan 25, 2018
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
501
18.16%
424
-11.11%
477
-96.77%
Cost of revenue
44,138
29,682
34,772
Unusual Expense (Income)
NOPBT
(43,637)
(29,258)
(34,295)
NOPBT Margin
Operating Taxes
4
13
Tax Rate
NOPAT
(43,641)
(29,258)
(34,308)
Net income
(39,834)
40.00%
(28,452)
-16.18%
(33,945)
-53.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
82,461
1,470
BB yield
-344.50%
-307.60%
Debt
Debt current
99
230
Long-term debt
99
313
(698)
Deferred revenue
Other long-term liabilities
1,313
560
Net debt
(61,318)
(92,710)
(31,606)
Cash flow
Cash from operating activities
(33,972)
(25,341)
(29,200)
CAPEX
(117)
Cash from investing activities
23,365
(57,354)
15,667
Cash from financing activities
(141)
82,394
1,653
FCF
(43,640)
(26,064)
(37,355)
Balance
Cash
61,516
93,253
30,908
Long term investments
Excess cash
61,491
93,232
30,884
Stockholders' equity
(731,149)
(691,309)
(661,054)
Invested Capital
783,334
781,686
692,467
ROIC
ROCE
EV
Common stock shares outstanding
42,589
10,273
3,186
Price
3.35
43.78%
2.33
1,453.33%
0.15
-85.29%
Market cap
142,673
496.06%
23,936
4,908.64%
478
-83.61%
EV
81,355
(68,774)
(30,917)
EBITDA
(43,633)
(29,258)
(34,223)
EV/EBITDA
2.35
0.90
Interest
10,807
Interest/NOPBT